Literature DB >> 17351674

The CDKN2a common variants: 148 Ala/Thr and 500 C/G in 3' UTR, and their association with clinical course of melanoma.

Katarzyna Monika Lamperska1, Anna Przybyła, Witold Kycler, Andrzej Mackiewicz.   

Abstract

Changes in CDKN2a gene are known to be linked with sporadic melanoma and hereditary predisposition to this cancer. In the Polish population mutations in the coding region of the CDKN2a gene are rather rare, therefore the attention has been focused on polymorphisms and alterations in uncoding regions such as 3' UTR. The aim of this study was to analyze two common polymorphisms, Ala148Thr and 500 C/G, and correlate them with the clinical course of melanoma. DNA from 285 patients was analyzed and found polymorphisms were correlated with the clinical parameters employing statistical methods. The obtained results allow us to conclude: (i) survival times of 500 C/G carriers vs. cumulating proportion surviving was not statistically significant; (ii) CDKN2a polymorphism 500 C/G correlated with Ala148Thr; (iii) no correlation was observed between the 500 C/G polymorphism and age of diagnosis, localization of primary melanoma and survival time; (iv) we did not find correlation between 500 C/G and type of cancer in the family; (v) changes in the CDKN2a gene were not found in patients with second cancer.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17351674

Source DB:  PubMed          Journal:  Acta Biochim Pol        ISSN: 0001-527X            Impact factor:   2.149


  7 in total

1.  Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.

Authors:  Cristina Pellegrini; Maria Giovanna Maturo; Claudia Martorelli; Mariano Suppa; Ambra Antonini; Dimitra Kostaki; Lucilla Verna; Maria Teresa Landi; Ketty Peris; Maria Concetta Fargnoli
Journal:  Melanoma Res       Date:  2017-06       Impact factor: 3.599

2.  3'UTR-CDKN2A and CDK4 Germline Variants Are Associated With Susceptibility to Cutaneous Melanoma.

Authors:  David Tovar-Parra; Sebastián Ramiro Gil-Quiñones; John Nova; Luz D Gutiérrez-Castañeda
Journal:  In Vivo       Date:  2021 May-Jun       Impact factor: 2.155

3.  Prevalence of variations in melanoma susceptibility genes among Slovenian melanoma families.

Authors:  Barbara Peric; Petra Cerkovnik; Srdjan Novakovic; Janez Zgajnar; Nikola Besic; Marko Hocevar
Journal:  BMC Med Genet       Date:  2008-09-19       Impact factor: 2.103

4.  Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom.

Authors:  Mark Harland; Anne E Cust; Celia Badenas; Yu-Mei Chang; Elizabeth A Holland; Paula Aguilera; Joanne F Aitken; Bruce K Armstrong; Jennifer H Barrett; Cristina Carrera; May Chan; Joanne Gascoyne; Graham G Giles; Chantelle Agha-Hamilton; John L Hopper; Mark A Jenkins; Peter A Kanetsky; Richard F Kefford; Isabel Kolm; Johanna Lowery; Josep Malvehy; Zighereda Ogbah; Joan-Anton Puig-Butille; Jordi Orihuela-Segalés; Juliette A Randerson-Moor; Helen Schmid; Claire F Taylor; Linda Whitaker; D Timothy Bishop; Graham J Mann; Julia A Newton-Bishop; Susana Puig
Journal:  Hered Cancer Clin Pract       Date:  2014-11-20       Impact factor: 2.857

5.  Oncogenic BRAF mutations and p16 expression in melanocytic nevi and melanoma in the Polish population.

Authors:  Małgorzata Mackiewicz-Wysocka; Patrycja Czerwińska; Violetta Filas; Elżbieta Bogajewska; Agata Kubicka; Anna Przybyła; Ewelina Dondajewska; Tomasz Kolenda; Andrzej Marszałek; Andrzej Mackiewicz
Journal:  Postepy Dermatol Alergol       Date:  2017-10-31       Impact factor: 1.837

6.  Significance of CDKN2A gene A148T variant in patients with bladder cancer.

Authors:  Edyta Borkowska; Adam Jędrzejczyk; Andrzej Kruk; Michał Pietrusiński; Magdalena Traczyk; Marek Rożniecki; Bogdan Kałużewski
Journal:  Cent European J Urol       Date:  2011-09-06

7.  Analysis of sequence variants in the 3'UTR of CDKN2A gene in melanoma patients.

Authors:  Anna Przybyła; Katarzyna Lamperska; Andrzej Mackiewicz
Journal:  Contemp Oncol (Pozn)       Date:  2015-09-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.